{"id":"neis-vac-c","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains polysaccharide capsular material from N. meningitidis serogroup C conjugated to a protein carrier, which enhances immunogenicity and promotes T-cell dependent B-cell responses. This generates both IgG antibodies and immunological memory, providing protection against invasive meningococcal disease caused by serogroup C strains.","oneSentence":"Neis-Vac-C is a meningococcal serogroup C conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:55.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C"}]},"trialDetails":[{"nctId":"NCT00891176","phase":"PHASE3","title":"Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-14","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":582},{"nctId":"NCT00327184","phase":"PHASE3","title":"Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":709}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Neis-Vac-C","genericName":"Neis-Vac-C","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Neis-Vac-C is a vaccine that has been studied for its effectiveness against Neisseria Meningitidis and Haemophilus Influenzae Type b. It is administered as part of a full vaccination course that includes Menitorix, a pneumococcal conjugate vaccine.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}